Jazz Pharmaceuticals has been granted a patent for the use of cannabidiol (CBD) in the treatment of treatment-resistant epilepsy (TRE), specifically for Dravet syndrome, myoclonic absence seizures, and febrile infection related epilepsy syndrome (FIRES). The patent also covers the use of CBD in combination with anti-epileptic drugs. The method involves administering a pharmaceutical composition containing at least 98% CBD to the patient, with a recommended dose ranging from 5 mg/kg/day to 25 mg/kg/day. GlobalData’s report on Jazz Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Jazz Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Jazz Pharmaceuticals's grant share as of September 2023 was 44%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11766411B2) describes a method for treating seizures associated with Dravet syndrome, a type of treatment-resistant epilepsy. The method involves administering a pharmaceutical composition containing a cannabidiol (CBD) drug substance to patients in need. The CBD drug substance must consist of at least 98% w/w CBD, with the remaining percentage comprising either cannabidiolic acid (CBDA), cannabidivarin (CBDV), delta-9 tetrahydrocannabinol (?9THC), or cannabidiol-C4 (CBD-C4), each within specific concentration limits.
The dose of CBD administered to the patient should range from about 5 mg/kg/day to about 25 mg/kg/day. The patent also includes various claims specifying different combinations and concentrations of CBD, CBDA, CBDV, ?9THC, and CBD-C4 in the CBD drug substance.
The method claims that the administration of CBD treats convulsive seizures and reduces seizure frequency. It further states that the administration of CBD can reduce total convulsive seizure frequency by at least 50% compared to the baseline period before CBD treatment.
The patent provides specific dosage options, including a dose of 10 mg/kg/day or 20 mg/kg/day. It claims that these doses can effectively treat convulsive seizures, reduce seizure frequency, and decrease convulsive seizure frequency by at least 50% compared to the baseline period.
In summary, the granted patent outlines a method for treating seizures associated with Dravet syndrome using a pharmaceutical composition containing a CBD drug substance. The patent specifies the required concentration of CBD and the permissible concentrations of other substances in the drug substance. It claims that the administration of CBD at specified doses can effectively treat convulsive seizures, reduce seizure frequency, and significantly decrease convulsive seizure frequency compared to the baseline period. This patent provides valuable information for researchers, medical professionals, and pharmaceutical companies working on developing treatments for Dravet syndrome.
To know more about GlobalData’s detailed insights on Jazz Pharmaceuticals, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
